Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13497360 | 0.82 | F2 (0.39) | SMN1; SMN2PKMLMNAMEN1TP53 | |
| SCHEMBL23258650 | 0.77 | SMN1; SMN2 (0.61) | SMN1; SMN2PKMMEN1TP53KMT2A | |
| SCHEMBL13497365 | 0.77 | CYP1A2 (0.38) | SMN1; SMN2PKMLMNAMEN1TP53 | |
| SCHEMBL12570010 | 0.76 | LMNA (0.43) | SMN1; SMN2PKMLMNAMEN1TP53 | |
| SCHEMBL8392709 | 0.75 | SMN1; SMN2 (0.96) | SMN1; SMN2PKMMEN1TP53KMT2A | |
| SCHEMBL17108513 | 0.75 | SMN1; SMN2 (0.58) | SMN1; SMN2PKMMEN1TP53KMT2A | |
| SCHEMBL16791197 | 0.75 | LMNA (0.46) | SMN1; SMN2PKMLMNAMEN1TP53 | |
| SCHEMBL22663957 | 0.74 | MEN1 (0.45) | SMN1; SMN2PKMLMNAMEN1TP53 | |
| SCHEMBL14595642 | 0.73 | PDK1 (0.46) | SMN1; SMN2PKMLMNAMEN1TP53 | |
| SCHEMBL2392837 | 0.73 | LMNA (0.45) | SMN1; SMN2PKMLMNAMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329906-B2 | Guanidinyl-substituted hydroxy-6-phenylphenanthridines | NYCOMED GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20100035913-A1 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiestrase (PDE) 4 inhibitors | NYCOMED GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| US-7585872-B2 | Guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (PDE) 4 inhibitors | NYCOMED GMBH (DE) | 2009-09-08 | — | — | US | disclosed |
| US-20070167482-A1 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors | ALTANA PHARMA AG (DE) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167482-A1 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors | PDE4A, PDE3A, PDE4B | SMN1; SMN2 3535/4885PKM 1568/4885LMNA 4282/4885 |
| US-20100035913-A1 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiestrase (PDE) 4 inhibitors | PDE4A, PDE4B, PDE4C | SMN1; SMN2 3546/4885PKM 1406/4885LMNA 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.